Inhibikase Therapeutics, Inc. (IKT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.44-8.28%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · IKT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -54.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
IKT — director transition
Dated 2026-10-20
Director — Dennis Berman: The filing discloses the resignation of a sitting director, which constitutes a departure, though the immediate appointment of a successor mitigates the impact.
Why it matters: The company reports cash runway to the Phase 3 data readout only if it gets timely exercise of warrants. Cash use and funding terms matter.
Worry ifThe next filing reports enough cash for planned trial work through the data readout. It shows no new financing that sharply raises the share count.
Less concerning ifThe next filing shows cash running out before the data readout, or new financing that sharply raises the share count.
Why it matters: The FDA decision will show whether IKT-001 gets this rare-disease status. The company has already filed an application.
Supportive ifThe FDA grants Orphan Drug Designation to IKT-001 for PAH.
Worry ifThe FDA rejects the application, or the company says it withdrew it.
Why it matters: A Phase 2b study appears in management's priorities, while the company also describes a global Phase 3 trial. A clear update can show how plans fit together.
Watch forThe company names the Phase 2b study's purpose, design, and start timing. It explains how the study relates to IMPROVE-PAH.
Also watch forThe company drops or delays the Phase 2b study, or gives no plan while still calling it a priority.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$225 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $616 loss on $10,000 · 6.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,127 loss on $10,000 · 41.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.